期刊文献+

抑制CC类趋化因子配体5基因表达对乳腺癌细胞增殖能力的影响 被引量:1

Effects of down-regulation of CC chemokine ligand 5 ( CCL5 ) on proliferation of human breast cancer cells in vitro
原文传递
导出
摘要 目的探讨抑制CC类趋化因子配体5(CCL5)基因表达对人乳腺癌细胞增殖能力的影响。方法用特异性CCL5 RNA干扰(RNAi)序列慢病毒载体感染人乳腺癌细胞MCF-7和MDA-MB-231,分别为KD1组和KD2组;另在MCF-7和MDA-MB-251细胞中分设阴性病毒载体感染的阴性对照组(NC1组和NC2组)和未感染组(CON1组和CON2组)。采用实时定量逆转录聚合酶链反应(RT—PCR)检测转染病毒后乳腺癌细胞中CCL5的表达,四甲基偶氮唑蓝(MTF)比色法和流式细胞术(FACS)分析细胞的增殖情况,平板克隆形成实验观察细胞的克隆形成能力。结果CCL5 RNAi慢病毒可显著降低MCF-7和MDA-MB-231细胞中CCL5基因的表达。MTT法检测结果显示,在不同的培养时间,MCF-7和MDA-MB-231细胞的KD组、NC组与CON组细胞培养上清一值差异均无统计学意义(均P〉0.05)。FACS分析结果显示,KD1组、NC1组和CON1组的增殖指数(PI)值分别为0.48±0.03、0.43±0.01和0.45±0.02;KD2组、NC2组和CON2组的PI值分别为0.48±0.02、0.44±0.05和0.47±0.02(两两比较,均P〉0.05)。荧光显微镜下观察显示,KD组的克隆体积及每克隆的细胞数明显小于NC组和CON组。KD1组和KD2组克隆数目(0.34±0.08和0.33±0.10)明显少于NC1组(0.81±0.12)、NC2组(0.97±0.09)、CON1组(0.92±0.12)和CON2组(1.04±0.07),差异有统计学意义(P〈0.05)。结论CCL5基因的表达下调对乳腺癌MCF-7和MDA-MB-231细胞群体倍增时间无明显影响,但可显著降低细胞的克隆形成能力,从而使肿瘤细胞的恶性增殖受到抑制。 Objective To investigate the effect of suppression of CCL5 ligand gene on the proliferation of human breast cancer cells. Methods A lentiviral vector carrying a short interfering RNA (siRNA) targeting CCL5 was transfeeted into human breast cancer cell line MCF-7 and MDA-MB-231 cells. The expression of CCL5 mRNA in the cells was detected by real-time PCR. The proliferation of MCF-7 and MDA-MB-231 cells was assessed by MTT assay and FACS assay, and the colony formation ability of both cell lines were measured, respectively. Results Real time PCR showed a good knockdown effect of CCL5 in both cell-lines. Colony-forming assay showed that the ability of colony formation of MCF-7/CCLS-siRNA and MDA-MB-231/CCLS-siRNA was decreased markedly. The colony number of MCF-7/CCLS-siRNA group was (0.34 ±0.08), significantly lower than 0.81 ±0.12 in the MCF-7/CCIS-N group and 0.92 ±0.12 in the MCF-7 group (P 〈 0.05). The colony number of MDA-MB-231/CCLS-siRNA group was 0.33 ± 0. 10, significantly lower than 0.97 ±0.09 in the MDA-MB-231/CCLS-N group and 1.04 ±0.07 in the MDA-MB- 231 group (P 〈0.05). However, MTT assay revealed that the proliferation of MCF-7/CCLS-siRNA cells was not significantly different from that of MCF-7/CCLS-N or MCF-7 cells, respectively ( P 〉 0.05 ), and the same result was found in MDA-MB-231 cells. FACS assay showed that the proliferation index (PI) of groups MCF-7/CCLS-siRNA, MCF-7/CCLS-N and MCF-7 were 0.48 ± 0.03, 0.43 ± 0.01 and 0.45 ± 0.02. The PI of groups MDA-MB-231/CCLS-siRNA, MDA-MB-231/CCLS-N and MDA-MB-231 cells were 0.48 ± 0.02, 0.44 ±0.05 and 0.47 ± 0.02. There was no statistical difference among them ( P 〉 0.05 ).Conclusion The down-regulation of CCL5 gene Jin human breast cancer cells may significantly suppress their colony formation ability, rather than affecting their population doubling time to some extent.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2011年第3期174-177,共4页 Chinese Journal of Oncology
基金 湖北省卫生厅基金(JX3A14)
关键词 乳腺肿瘤 CC类趋化因子配体5 基因表达 细胞增殖 Breast neoplasms CC chemokine ligand 5 Geue expression Cell proliferation
  • 相关文献

参考文献11

  • 1Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES Jevels with disease course in patients with breast or cervical cancer. Clin Cancer Res, 2001, 7:285-289.
  • 2匡军秀,王卫星,孙圣荣,王万荣.人CCL5基因RNA干扰慢病毒载体的构建[J].中华实验外科杂志,2009,26(2):174-176. 被引量:4
  • 3Robinson SC, Scott KA, Wilson JL, et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res, 2003, 63:8360-8365.
  • 4Karnuub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stronm promote breast cancer metastasis. Nature, 2007, 449:557-563.
  • 5Pinilla S, Ah E, Abdul Khalek FJ, et al. Tissue resident stem cells produce CCI5 under the influence of cancer cells and thereby promote breast cancer eell invasion. Cancer Lett, 2009, 254:80- 85.
  • 6史业辉,李慧,曹水,刘虹,魏枫,王旭东,任秀宝.表达RANTES基因的腺病毒载体构建及抗肿瘤作用研究[J].中华肿瘤防治杂志,2006,13(14):1043-1046. 被引量:1
  • 7Jayasinghe MM, Golden JM, Nair P, et al. Tumor-derived CC15 does not contribute to breast cancer progression. Breast Cancer Rcs Treat, 2008, 111 :511-521.
  • 8姚晓莉,童鹤翔,涂毅,姚峰,王卫星,孙圣荣.CCL5及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592. 被引量:15
  • 9王万荣,姚峰,姚晓莉,匡军秀,王卫星,孙圣荣.多种人乳腺癌细胞株CCL5表达和其侵袭能力关系的初步研究[J].临床外科杂志,2008,16(2):111-113. 被引量:4
  • 10Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002, 2:442-454.

二级参考文献25

  • 1姚晓莉,童鹤翔,涂毅,姚峰,王卫星,孙圣荣.CCL5及其受体在乳腺癌组织中的表达及其意义[J].中华实验外科杂志,2007,24(5):590-592. 被引量:15
  • 2Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 2007,449 : 557 -563.
  • 3Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med,2003 ,198 :1381-1389.
  • 4Jayasinghe MM, Golden JM, Nair P, et al. Tumor-derived CCL5 does not contribute to breast cancer progression. Breast Cancer Res Treat, 2008,111:511-521.
  • 5Adler EP, Lemken CA, Katchen NS, et al. A dual role for tumor-derived chemokine RANTES ( CCL5 ). Immunol Lett, 2003,90: 187- 194.
  • 6Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res ,2001,7:285-289.
  • 7Azenshtein E, Luboshits G, Shina S, et al. The CC ehemokine RANTES in breast carcinoma progression:regulation of expression and potential mechanisms of premalignant activity. Cancer Res, 2002,62 : 1093-1102.
  • 8Vaday GG, Peehl DM, Kadam PA, et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate,2006,66:124-134.
  • 9Sugasawa H, Iehikura T, Tsujimoto H, et al. Prognostic significance of expression of CCLS/RANTES receptors in patients with gastric caneer. J Surg Oneol,2008,97:445-450.
  • 10Lavergne E, Combadiere C, Iga M, et al. Intratumoral CC ehemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immuno1,2004 ,173 :3755-3762.

共引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部